KIDNEY AND HEART INVOLVEMENT IN ARTERIAL HYPERTENSION: EVOLUTION OF VIEW FROM R. BRIGHT AND E.M. TAREEV TO PRESENT DAYS
Abstract
Evolution of concepts of pathogenesis and treatment of heart and kidney involvement as integrated continuum are described
About the Authors
V. I. Podzolkov
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздравсоцразвития России»
Russian Federation
Russian Federation
V. A. Bulatov
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздравсоцразвития России»
Russian Federation
Russian Federation
References
1. Шляхто Е.В., Конради А.О. Роль генетических факторов в ремоделировании сердечно-сосудистой системы при гипертонической болезни / / Артериал. гипертензия. — 2002. — № 8. — С. 107—114.
2. Adler С.Р. Polyploidization and augmentation of heart muscle cells during normal cardiac growth and in cardiac hypertrophy / / The Development and Regenerative Potential of Cardiac Muscle / Eds J.O. Oberpriller, J.C. Oberpriller, A. Mauro. — Edition Chur: Harwood Academic Publishers, 1991. — P. 227—252.
3. Agabiti-Rosei E., Muiesan M.L. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues // Blood Press. - 2001. - Vol. 10. - P. 288-298.
4. Banerjee P., Clark A.L., Nikitin N., Cleland J.G. Diastolic heart failure. Paroxysmal or chronic? // Eur. J. Heart Fail. — 2004.-Vol. 6 .-P.427-431.
5. Bianchi S., Bigazzi R-, Campese V.M. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications //Am. J. Kidney Dis. — 1999. — Vol. 34. - P. 973-995.
6. Bigazzi R-, Bianchi S., Baldari D. et al. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension / / J. Hypertens. - 1998. - Vol. 16. - P. 1325-1333.
7. Brown M.J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) // Lancet. — 2000. - Vol. 356. - P. 366-372.
8. Bulatov V.A., Stenehjem A., Os I. Left ventricular mass assessed by electrocardiography and albumin excretion rate as a continuum in untreated essential hypertension // J. Hypertens. - 2001. - Vol. 19. - P. 1473-1478.
9. Caetano E.R., Zatz R-, Saldanha L.B., Praxedes J.N. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure / / Hypertension. — 2001. — Vol. 38. — P. 171-176.
10. Campese V.M., Bianchi S., Bigazzi R- Is microalbuminuria a predictor of cardiovascular and renal disease in patients with essential hypertension? // Curr. Opin. Nephrol. Hypertens. — 2000. — Vol. 9. — P. 143—147.
11. Col! E., Campos B., Gonzalez-Nunez D. et ai Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency // J. Nephrol. — 2003. — Vol. 16. — P. 357-364.
12. DiBona G.F. Neural control of renal function: role of renal alpha adrenoceptors//J. Cardiovasc. Pharmacol. - 1985. — Vol. 7, suppl. 8. — P. S18—23.
13. Dzau V.J., Antman E.M., Black H.R. et ai The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) / / Circulation. — 2006. — Vol. 114. — P. 2850-2870.
14. Dzau V.J., Antman E.M., Black H.R. etal. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions// Circulation. - 2006. - Vol. 114,- P.2871-2891.
15. Hesse I.F., Johns E.J. The subtype of alpha-adrenoceptor involved in the neural control of renal tubular sodium reabsorption in the rabbit / / J. Physiol. — 1984. — Vol. 352. — P. 527-538.
16. Hillege H.L., Girbes A.R., de Kam P.J. et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure / / Circulation. — 2000. — Vol. 102. — P. 203-210.
17. Kannel W.B. Prevalence and natural history of electrocardiographic left ventricular hypertrophy // Am. J. Med. — 1983.-Vol. 75.-P .4 -1 1 .
18. Kannel W.B., Stampfer M.J., Castelli W.P., Verier J. The prognostic significance of proteinuria: the Framingham study //Am. Heart J. - 1984.-Vol. 108. - P. 1347-1352.
19. Leehey D.J., Singh A.K., Alavi N., Singh R. Role of angiotensin II in diabetic nephropathy // Kidney Int. Suppl. — 2000. - Vol. 77. - P. S93-98.
20. Locatelli F, Marcelli D., Conte F. et al. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto / / Nephrol. Dial. Transplant. — 2000. — Vol. 15, suppl. 5. — P. 69—80.
21. Luke R.G. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease // Nephrol. Dial. Transplant. — 1999. - Vol. 14. - P. 2271-2278.
22. Magri P., Rao M.A., Cangianiello S. et at. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin 11 antagonism // Circulation. - 1998. - Vol. 98. - P. 2849-2854.
23. MayetJ., Foale R.A. Changes in left ventricular function in cardiac hypertrophy// Left Ventricular Hypertrophy / Ed. D.J. Sheridan. — London: Churchill, 1998. — P. 93—99.
24. McMurray J.J.V., Stewart S. The burden of heart failure // Eur. Heart J. Suppl. - 2003. - Vol. 5. - P. 13-113.
25. Meyrier A., Simon P. Nephroangiosclerosis and hypertension: things are not as simple as you might think/ / Nephrol. Dial. Transplant. — 1996. — Vol. 11. — P. 2116—2120.
26. Osborn J.L., Holdaas H., Thames M.D., DiBona G.F. Renal adrenoceptor mediation of antinatriuretic and renin secretion responses to low frequency renal nerve stimulation in the dog// Circ. Res. - 1983. - Vol. 53. - P. 298-305.
27. Paul M., Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system // J. Cardiovasc. Pharmacol. — 1992. - Vol. 19, suppl. 5. — P. S5I-58.
28. Pedrinelli R. Microalbuminuria in essential hypertension. A marker of systemic vascular damage? // Nephrol. Dial. Transplant. - 1997. - Vol. 12. - P. 379-381.
29. Phillips R.A., Diamond J.A. Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension // Hypertension: a Companion to Brenner and Rector’s The Kidney / Eds S. Oparil, M.A. Weber. — Philadelphia: W.B. Saunders, 2000. - P. 244-277.
30. Phillips R.A., Goldman M.E., Ardeljan M. etal. Determinants of abnormal left ventricular filling in early hypertension // J. Am. Coll. Cardiol. - 1989. - Vol. 14. - P. 979-985.
31. Ritz E., Orth S., Weinreich T., Wagner J. Systemic hypertension versus intraglomerular hypertension in progression // Kidney Int. — 1994. — Vol. 45. — P. 438—442.
32. Rizzoni D.} Castellano M., Porteri E. etal. Effects of low and high doses of fosinopril on the structure and function of resistance arteries // Hypertension. — 1995. — Vol. 26. — P. 118—123.
33. Ruggenenti P., Perna A., Mosconi L. et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. «Gruppo ItalianodiStudi EpidemiologiciinNefrologia»(GISEN)// Kidney lnt. - 1998. - Vol. 53. - P. 1209-1216.
34. Ruilope L.M. Kidney dysfunction: a sensitive predictor of cardiovascular risk // Am. J. Hypertens. — 2001. — Vol. 14. — P. 213S-217S.
35. Ruilope L.M. The kidney as a sensor of cardiovascular risk in essential hypertension / / J. Am. Soc. Nephrol. — 2002. — Vol. 13, suppl. 3. - P. SI65-168.
36. Ruilope L.M., Campo C., Rodriguez-Artalejo F. et al. Blood pressure and renal function: therapeutic implications / / J. Hypertens. - 1996. - Vol. 14. - P. 1259-1263.
37. Sharma A.M. Renal involvement in hypertensive cardiovascular disease // Eur. Heart J. — 2003. — Vol. 5. — P. F12—F18.
38. Sheridan D.J., Kingsbury M.P. Mechanisms od reduced coronary reserve in cardiac hypertrophy// Left Ventricular Hypertrophy. 1st ed. / Ed. D.J. Sheridan. — London: Churchill, 1998. - P. 135-143.
39. Silberberg J.S., Barre P.E., Prichard S.S., Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease // Kidney Int. — 1989. — Vol. 36. — P. 286—290.
40. Staessen J.A., Wang J.G., Ginocchio G. et al. The deletion/ insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk//J. Hypertens. — 1997.-Vol. 1 5 ,- P. 1579-1671.
41. The GISEN Gropu. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) // Lancet. — 1997. — Vol. 349. - P. 1857-1863.
42. Tracy R. Ishii T. What is «nephrosclerosis»? Lessons from the US, Japan, and Mexico/ / Nephrol. Dial. Transplant. — 2000. - Vol. 15. - P. 1357-1366.
43. USRDS: U.S. Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute ofDiabetesand Digestive and Kidney Diseases. — Bethesda, 2002.
44. Viberti G.C., Hill R.D., Jarrett R.J. et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus // Lancet. — 1982. — Vol. 1. — P. 1430-1432.
45. Volpe M., Magri P., Rao M.A. etal. Intrarenal determinants of sodium retention in mild heart failure: effects of angiotensin- converting enzyme inhibition / / Hypertension. — 1997. - Vol. 30. - P. 168-176.
46. Weber K.T., Sun Y, DhallaA.K. Extracellular matrix and fibrosis in cardiac hypertrophy // Left Ventricular Hypertrophy. 1st ed. / Ed. D.J. Sheridan. — London: Churchill, 1998. — P. 37—44.
47. Weisstuch J.M., Dworkin L.D. Does essential hypertension cause end-stage renal disease? / / Kidney Int. Suppl. — 1992. - Vol. 36. - P. S33-37.
48. Yamazaki T., Komuro I., Yazaki Y. Triggers for cardiac hypertrophy// Left Ventricular Hypertrophy. 1st ed. / Ed. D.J. Sheridan. — London: Churchill, 1998. — P. 71—76.
49. Zanchetti A., Hansson L., Dahlof B. et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group / / J. Hypertens. — 2001. — Vol. 19. — P. 1149—1159.
Review
Views: 24
Email this article 